Author

Arun J Sanyal 1

1 Virginia Commonwealth University Center for Clinical and Translational Research

Advances in the medical therapy of NASH

Arun J Sanyal

Introduction

Arun J Sanyal

New hope for fatty liver disease

Arun J Sanyal

Obesity, non-alcoholic fatty liver disease (NAFLD) and liver cancer

Arun J Sanyal

Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for Nonalcoholic Steatohepatitis

Zobair Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip Newsome, David Sheridan, James Trotter, Whitfield Knapple, Eric Lawitz, Kris V. Kowdley, Aldo Montano-Loza, Jérôme Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe

REGENERATE: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY OF OBETICHOLIC ACID THERAPY FOR NONALCOHOLIC STEATOHEPATITIS

Vlad Ratziu, Arun J Sanyal, Leigh MacConell, Reshma Shringarpure, Tonya Marmon, David Shapiro, Zobair Younossi

TREATMENT WITH OBETICHOLIC ACID IN PATIENTS WITH NASH DOES NOT SHOW INCREASED MARKERS OF LIVER TOXICITY BASED ON EVALUATION OF DRUG-INDUCED SERIOUS HEPATOTOXICITY (EDISH)

Arun J Sanyal, Paul Pockros, Amrik Shah, Reshma Shringarpure, David Shapiro, Aldo Trylesinski, Leigh MacConell

Trial presentation: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

Arun J Sanyal

Item 1 - 8 / 8
1